WOOJUNG BIO Inc Asset Resilience Ratio
WOOJUNG BIO Inc asset resilience ratio. WOOJUNG BIO Inc (215380) has an Asset Resilience Ratio of 29.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 215380 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of WOOJUNG BIO Inc (2016–2025)
Asset resilience ratio of WOOJUNG BIO Inc from 2016 to 2025. This chart shows how WOOJUNG BIO Inc's Asset Resilience Ratio has changed over time. Read WOOJUNG BIO Inc (215380) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down WOOJUNG BIO Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 215380 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩35.33 Billion | 29.05% |
| Total Liquid Assets | ₩35.33 Billion | 29.05% |
Asset Resilience Insights
- Very High Liquidity: WOOJUNG BIO Inc maintains exceptional liquid asset reserves at 29.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
WOOJUNG BIO Inc Industry Peers by Asset Resilience Ratio
Compare WOOJUNG BIO Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
WOOJUNG BIO Inc Asset Resilience Ratio by Year (2016–2025)
WOOJUNG BIO Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for WOOJUNG BIO Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.33% | ₩285.00 Million ≈ $193.14K |
₩86.80 Billion ≈ $58.82 Million |
+0.07pp |
| 2024-12-31 | 0.26% | ₩248.30 Million ≈ $168.27K |
₩94.70 Billion ≈ $64.18 Million |
+0.11pp |
| 2023-12-31 | 0.15% | ₩150.00 Million ≈ $101.65K |
₩98.33 Billion ≈ $66.64 Million |
-4.92pp |
| 2022-12-31 | 5.07% | ₩4.82 Billion ≈ $3.27 Million |
₩94.99 Billion ≈ $64.38 Million |
-1.66pp |
| 2021-12-31 | 6.74% | ₩6.74 Billion ≈ $4.57 Million |
₩100.14 Billion ≈ $67.86 Million |
-15.88pp |
| 2020-12-31 | 22.62% | ₩15.79 Billion ≈ $10.70 Million |
₩69.82 Billion ≈ $47.31 Million |
-3.93pp |
| 2019-12-31 | 26.55% | ₩15.30 Billion ≈ $10.37 Million |
₩57.63 Billion ≈ $39.06 Million |
-12.30pp |
| 2018-12-31 | 38.85% | ₩17.41 Billion ≈ $11.80 Million |
₩44.81 Billion ≈ $30.37 Million |
+4.06pp |
| 2017-12-31 | 34.80% | ₩10.93 Billion ≈ $7.40 Million |
₩31.40 Billion ≈ $21.28 Million |
-64.24pp |
| 2016-12-31 | 99.04% | ₩11.88 Billion ≈ $8.05 Million |
₩12.00 Billion ≈ $8.13 Million |
-- |
About WOOJUNG BIO Inc
Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and e… Read more